Scalp care composition containing kangaroo claw extract as well as preparation and application of scalp care composition

Abstract

The invention discloses a scalp care composition containing a kangaroo claw extract. The scalp care composition is prepared from the following components: the kangaroo claw extract, arginine, glycine and soluble 17-type collagen. The invention further discloses a preparation method and application of the scalp care composition. According to the composition disclosed by the invention, the kangaroo claw extract-arginine-glycin-17 type collagen is compounded and combined, so that the activity of MMP-12 is inhibited, and the generation of elastin fragments is reduced; the expression of CyclinD1 is up-regulated, and the cell cycle of the hair papilla is activated; the inflammatory factor level is reduced, the scalp steady state is recovered, and the health state of the scalp microenvironment can be comprehensively and effectively maintained.

Description

Technical Field

[0001] This invention belongs to the field of cosmetic technology, specifically relating to a scalp care composition containing kangaroo paw extract and its preparation and application. Background Technology

[0002] The balance of the scalp microenvironment is crucial for overall scalp health and normal hair growth. Recent studies have shown that abnormally increased activity of matrix metalloproteinases (MMPs) can lead to excessive degradation of the scalp extracellular matrix, thus affecting scalp health. CyclinD1 is a key protein in cell cycle regulation, promoting the normal proliferation and renewal of scalp tissue cells. Furthermore, persistent local inflammation can also negatively impact scalp tissue, disrupting the scalp microecological balance.

[0003] Existing patents, such as FR2778558A1 and US20060074108A1, propose the use of broad-spectrum MMP inhibitors to prevent hair loss, advocating the incorporation of metalloproteinase inhibitors into topical formulations to slow down hair follicle matrix damage. However, these patents do not provide selective inhibition of MMP-12, which may inhibit other essential MMPs, leading to abnormal keratinization; nor do they contain any formulation ingredients that can simultaneously activate dermal papilla proliferation signals (such as Cyclin D1).

[0004] Kangaroo paw (Anigozanthos flavidus) extract, derived from the kangaroo paw flower, is rich in phenylphenalenones and flavonoids (such as tetrahydroxyflavone and rutin), thus possessing potential anti-inflammatory and antioxidant activities. Patents AU 2017345384 A1 and CN109937031B only describe it as a general anti-aging / firming ingredient, without addressing hair loss or MMP-12 / Cyclin D1 mechanisms. Its efficacy is targeted at skin wrinkles rather than the hair follicle matrix, and it does not combine with amino acids or collagen to construct the scalp microenvironment.

[0005] Patent EP1482894A2 reports that L-arginine oligomers can improve hair shine through vasodilation; patents US6358502B1 and EP0415598A1 show that N-acetylglycine promotes hair growth in rats; and patent US11298372B2 demonstrates that stable type 17 collagen can inhibit hair follicle miniaturization. However, for collagen or peptides, different amino acid compositions and quantities result in different effects. Existing patent literature mostly focuses on single components or emphasizes blood flow / structural support, and has not yet demonstrated the synergistic use of amino acids and collagen to precisely inhibit MMP-12 while simultaneously activating Cyclin D1.

[0006] The existing technology has the following problems: (1) The target is not focused. Broad-spectrum MMP inhibition may interfere with normal matrix renewal, while there is a lack of research on selective regulation of MMP-12; (2) There is a lack of a dual-pathway scheme of "enzyme inhibition + proliferation promotion". Existing plant or amino acid preparations often only provide nutrition or antioxidants, and fail to inhibit matrix metalloproteinases and simultaneously upregulate Cyclin D1, a key protein in the hair papilla cell cycle; (3) The formulation is not synergistic enough. There is no published literature showing that multiple components can be combined to achieve a triple effect of MMP-12 / Cyclin D1 / inflammation; (4) The immune-matrix positive feedback is difficult to interrupt. Single metalloproteinase inhibitors or simple anti-inflammatory components are difficult to take into account both extracellular matrix protection and hair follicle proliferation signal maintenance. Summary of the Invention

[0007] One object of the present invention is to provide a scalp care composition containing kangaroo paw extract in order to address the above-mentioned technical problems.

[0008] Another object of the present invention is to provide a method for preparing the scalp care composition containing kangaroo paw extract.

[0009] Another object of the present invention is to provide the application of the scalp care composition containing kangaroo paw extract.

[0010] To achieve the above-mentioned objectives, the present invention provides the following technical solution:

[0011] In a first aspect, the present invention provides a scalp care composition containing kangaroo paw extract, comprising the following components: kangaroo paw extract, arginine, glycine, and soluble type 17 collagen.

[0012] In a preferred embodiment, the scalp care composition comprises, by weight percentage: 2–10% kangaroo paw extract, 1–8% arginine, 1–5% glycine, and 0.05–0.5% soluble type 17 collagen.

[0013] In a preferred embodiment, the scalp care composition comprises, by weight percentage: 2% kangaroo paw extract, 8% arginine, 1% glycine, and 0.05% soluble type 17 collagen.

[0014] In a preferred embodiment, the kangaroo paw extract is prepared by the following steps: pulverizing dried petals of kangaroo paw flower, refluxing them with 70% ethanol at a mass-to-volume ratio of 1:10 at 70°C for 120 min; filtering to collect the supernatant, and then re-extracting it with 70% ethanol for 60 min; combining the filtrates and concentrating under reduced pressure at 55°C and -0.08 MPa to obtain a viscous extract, which is then spray-dried to obtain the kangaroo paw extract.

[0015] In a preferred embodiment, the scalp care composition containing kangaroo paw extract further includes solvents and / or excipients.

[0016] Preferably, the solvent is one or more of water, butanediol, and glycerol.

[0017] Preferably, the excipient is one or more of p-hydroxyacetophenone, phenoxyethanol, sodium benzoate, and ethylhexylglycerin.

[0018] In a second aspect, the present invention provides a method for preparing the scalp care composition containing kangaroo paw extract, comprising the following steps:

[0019] S1. Dissolve arginine and glycine in purified water at 65°C in sequence, and stir until clear;

[0020] S2. Cool the solution to 45°C, add kangaroo paw extract, and stir until completely dissolved;

[0021] S3. Maintain the temperature at 40°C, add soluble type 17 collagen, and stir until homogeneous to obtain the scalp care composition containing kangaroo paw extract.

[0022] Thirdly, the present invention also provides a scalp care product comprising the scalp care composition containing kangaroo paw extract.

[0023] Preferably, the scalp care composition containing kangaroo paw extract accounts for 0.05-1% of the mass of the shampoo and conditioner.

[0024] Preferably, the hair care product is any one of shampoo, hair essence, conditioner, and hair mask.

[0025] Preferably, the hair care product is a shampoo, which comprises the following components by weight percentage: 9% sodium C14-16 olefin sulfonate, 5% cocamidopropyl betaine, 3% sodium lauroyl sarcosinate, 2% cocamidopropyl MEA, 1% sodium cocoyl ethanesulfonate, 0.2% guar hydroxypropyl trimethylammonium chloride, 1% polydimethylsiloxane, 1% ethylene glycol distearate, 0.4% sodium benzoate, 0.5% phenoxyethanol, 0.25% trihydroxystearin, 0.1% sodium citrate, 0.2% citric acid, 0.1% disodium EDTA, 0.5% fragrance, 0.05-1% of the scalp care composition containing kangaroo paw extract, and the balance being deionized water.

[0026] Preferably, the hair care product is a shampoo essence, which is composed of the following components by weight percentage: 5% butylene glycol, 3% propylene glycol, 0.05% xanthan gum, 0.6% p-hydroxyacetophenone, 0.8% 1,2-hexanediol, 0.02% disodium EDTA, 0.02% fragrance, 0.05-1% of the scalp care composition containing kangaroo paw extract of Example 1, and the balance being deionized water.

[0027] Fourthly, the present invention provides the use of the scalp care composition containing kangaroo paw extract for inhibiting the activity of matrix metalloproteinase MMP-12.

[0028] Fifthly, the present invention provides the use of the scalp care composition containing kangaroo paw extract for promoting Cyclin D1 expression.

[0029] In a sixth aspect, the present invention provides the application of the scalp care composition containing kangaroo paw extract for suppressing inflammatory responses.

[0030] In a seventh aspect, the present invention provides the application of the scalp care composition containing kangaroo paw extract for maintaining a healthy microenvironment in scalp tissue.

[0031] The composition of this invention, through a complex combination of kangaroo paw extract, arginine, and glycine-17 type collagen, inhibits MMP-12 activity and reduces elastin fragmentation; upregulates Cyclin D1 expression, activating the dermal papilla cell cycle; and reduces inflammatory factor (TNF-α) levels, restoring scalp homeostasis. In vitro models have validated that this composition can achieve both matrix protection and enhanced cell viability. In the composition of this invention, each component has a clear division of labor and synergistic effect in scalp care and hair loss prevention. Kangaroo paw extract is rich in polyphenols (such as quercetin, kaempferol, caffeic acid, and related derivatives), which can specifically inhibit the overexpression of MMP-12, thereby slowing down the degradation of the hair follicle extracellular matrix, promoting the entry of hair follicles into the growth phase, and simultaneously exerting antioxidant and anti-inflammatory effects to improve the scalp microenvironment. Arginine, as a precursor to nitric oxide, can dilate blood vessels, improve the nutrient supply to dermal papilla cells, provide raw materials for keratin synthesis, and enhance hair shaft toughness. Glycine, an important amino acid component of collagen, not only promotes collagen synthesis and repairs the hair follicle basement membrane but also possesses anti-inflammatory and soothing effects, maintaining the stability of the hair follicle microenvironment. Soluble type 17 collagen plays a crucial role in hair follicle stem cell adhesion and hair follicle regeneration, preventing stem cell depletion, repairing the dermal-epidermal junction, and enhancing hair anchoring. Through the synergistic effect of each component, this composition complements each other in three aspects: signal regulation, nutritional support, and structural repair. Kangaroo claw flower provides core molecular target regulation, amino acids provide substrates for collagen and keratin synthesis and improve scalp circulation, and type 17 collagen maintains hair follicle structure and stem cell activity. These three components mutually promote each other, jointly achieving the effects of inhibiting hair follicle miniaturization, prolonging the growth phase, and improving hair adhesion, thereby significantly enhancing the anti-hair loss effect, which is significantly better than using each component alone.

[0032] This invention, through a unique combination of kangaroo paw extract with specific amino acids (arginine and glycine) and type 17 collagen, for the first time clearly proposes a synergistic mechanism of action targeting MMP-12 activity inhibition, Cyclin D1 expression promotion, and local inflammation regulation. Compared with existing technologies, the composition of this invention can more comprehensively and effectively maintain the health of the scalp microenvironment, demonstrating significant technological innovation and practical value. Attached Figure Description

[0033] Figure 1 The mRNA expression level of MMP-12 is shown.

[0034] Figure 2 The mRNA expression level of Cyclin D is shown.

[0035] Figure 3 The mRNA expression level of TNF-α is shown. Detailed Implementation

[0036] To facilitate understanding of the present invention, a more complete description will be given below with reference to the accompanying drawings and specific embodiments. Preferred embodiments of the invention are shown in the drawings. However, the invention can be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to provide a thorough and complete understanding of the disclosure of the invention.

[0037] In the description of this invention, unless otherwise explicitly defined, terms such as heating, cleaning, weighing, and freezing should be interpreted broadly. Those skilled in the art can reasonably determine the specific meaning of the above terms in this invention in conjunction with the specific content of the technical solution.

[0038] In the description of this invention, references to terms such as "some embodiments" and "examples" indicate that the specific methods or materials described in connection with that embodiment or example are included in at least one embodiment or example of the invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiments or examples. Furthermore, the specific methods and materials described may be combined in any suitable manner in one or more embodiments or examples.

[0039] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.

[0040] Unless otherwise specified, the experimental methods used in the following examples and comparative examples are conventional methods, and the materials and reagents used are commercially available unless otherwise specified.

[0041] Preparation of kangaroo paw extract

[0042] Dried petals of *Anigozanthos flavidus*, grown in Western Australia, were selected. The petals were pulverized, and the raw material was mixed with 70% (volume fraction) food-grade ethanol at a ratio of 1:10 (mass:volume (g / mL)) in a jacketed extraction vessel. The mixture was refluxed at 70℃ for 120 min. The supernatant was filtered and extracted a second time with 70% (volume fraction) ethanol at a ratio of 1:10 (mass:volume (g / mL)) at 70℃ for 60 min. The filtrates were combined and concentrated under reduced pressure at 55℃ and -0.08 MPa to obtain a viscous extract. This extract was then placed in a spray drying tower and sprayed with inlet air at 165℃ and outlet air at 85℃ to obtain a light brown powder with a moisture content ≤5%, which is the kangaroo paw extract.

[0043] Example 1

[0044] A scalp care composition containing kangaroo paw extract, comprising, by weight percentage: 2% kangaroo paw extract, 8% arginine, 1% glycine, 0.05% soluble type 17 collagen, and the balance being water.

[0045] The preparation steps of this scalp care composition are as follows:

[0046] (1) Add 65℃ purified water to the clean tank, dissolve arginine and glycine in sequence, stir until clear, and then cool down;

[0047] (2) Cool the solution to 45°C, slowly add kangaroo paw extract powder, and stir at 500 rpm for 20 minutes to completely dissolve it;

[0048] (3) Maintain the temperature at 40°C, add soluble type 17 collagen, and stir at 500 rpm for 15 minutes until homogeneous to obtain a scalp care composition containing kangaroo paw extract.

[0049] Regular auxiliary materials can be added and mixed evenly at 40℃ according to actual needs.

[0050] Example 2

[0051] A scalp care composition containing kangaroo paw extract is prepared in the same way as in Example 1, except that, by mass percentage, the scalp care composition consists of the following components: 2% kangaroo paw extract, 1% arginine, 1% glycine, 0.05% soluble type 17 collagen, and the balance being water.

[0052] Example 3

[0053] A scalp care composition containing kangaroo paw extract is prepared in the same way as in Example 1, except that it consists of the following components by mass percentage: 10% kangaroo paw extract, 8% arginine, 5% glycine, 0.5% soluble type 17 collagen, and the balance being water.

[0054] Comparative Example 1

[0055] A scalp care composition, compared with Example 1, differs in that it does not contain kangaroo paw extract powder, 8% arginine, 1% glycine, 0.05% soluble type 17 collagen, and the remainder is water.

[0056] Comparative Example 2

[0057] A scalp care composition, compared with Example 1, differs in that the composition does not contain arginine, 2% kangaroo paw extract, 1% glycine, 0.05% soluble type 17 collagen, and the balance being water.

[0058] Comparative Example 3

[0059] A scalp care composition, compared with Example 1, differs in that the composition does not contain glycine, 2% kangaroo paw extract, 8% arginine, 0.05% soluble type 17 collagen, and the balance being water.

[0060] Comparative Example 4

[0061] A scalp care composition, compared with Example 1, differs in that the composition does not contain soluble type 17 collagen, 2% kangaroo paw extract, 8% arginine, 1% glycine, and the remainder is water.

[0062] Experimental Example 1

[0063] Assay for MMP-12 and Cyclin D1 expression in dermal papilla cells

[0064] 1.1 Test substance

[0065] The compositions of Examples 1-3 and the compositions of Comparative Examples 1-4 were used as test substances.

[0066] 1.2 Experimental Methods

[0067] Human primary dermal papilla cells in the logarithmic growth phase were seeded into sterile 96-well plates and cultured at 37°C and 5% CO2. After cell attachment, 10 μg / mL of the compositions from Example 1, Example 2, Example 3, Comparative Example 1, Comparative Example 2, Comparative Example 3, and Comparative Example 4 were added respectively. No composition was added to the blank group. The cells were then cultured for another 48 hours. The supernatant was aspirated, and the cells were washed with PBS, digested with trypsin, and centrifuged to collect the cell pellet. Take an appropriate amount of the sample to be tested, add liquid nitrogen, and grind it. Transfer the ground sample to an EP tube with 1 mL of Trizol, add 500 μL of chloroform, suspend and mix, let stand at room temperature for 15 min, and centrifuge at 4℃ and 12000 rpm for 10 min. Transfer the upper aqueous phase to a new EP tube, add an equal volume of pre-chilled isopropanol, invert and mix, and let stand at room temperature for 10 min. Centrifuge at 4℃ and 12000 rpm for 10 min, discard the supernatant, and collect the white precipitate, which is the RNA precipitate. Add 1 mL of pre-chilled 75% ethanol, mix, centrifuge at 4℃ and 8000 rpm for 3 min, discard the supernatant and residual ethanol, open the cap and let it air dry at room temperature for 5 min to allow the ethanol to evaporate as completely as possible. Add 50 μL of DEPC water to dissolve the RNA precipitate, and measure OD260 / 280 with a micro spectrophotometer. cDNA was synthesized by reverse transcription. The real-time quantitative PCR reaction system (20 μL) consisted of: 1 μL cDNA, 10 μL SYBR Green Mix, 0.4 μL each of primers (10 μM), and water to make up the difference.

[0068] The primer sequences are as follows:

[0069] MMP-12 forward primer: 5'-GCATAGTCCTGTTCCTGGAA-3';

[0070] MMP-12 reverse primer: 5'-CCCTGAGAAGCCCAATGATA-3';

[0071] Cyclin D1 forward primer: 5'-CGCGTACCCCGATGCCAAC-3';

[0072] Cyclin D1 reverse primer: 5'-CCAGGTGGCGACGATCTTCC-3';

[0073] β-Actin forward primer: 5'-AGAGCTACGAGCTGCCTGAC-3';

[0074] β-Actin reverse primer: 5'-AGCACTGTGTTGGCGTACAG-3'.

[0075] The formula for calculating relative expression levels is as follows:

[0076]

[0077] ΔCt q = Average Ct value of target gene in test group - Average Ct value of internal reference gene in test group

[0078] ΔCt cb = Average Ct value of target gene in control group - Average Ct value of internal reference gene in control group

[0079] 1.3 Experimental Results

[0080] Experimental results are as follows Figure 1 and Figure 2 As shown.

[0081] Depend on Figure 1As can be seen, Example 3 showed the strongest inhibition of MMP-12 gene expression, with an average reduction of approximately 43%. Comparative Example 1 almost lost its inhibitory ability, with only an 8% reduction, which falls within the experimental error range, indicating that kangaroo paw flower extract is the key component for inhibiting MMP-12. Comparative Example 2 still showed approximately 20% inhibition, but it was significantly weaker than that of Examples 1-3, indicating that arginine has a synergistic effect on the downregulation of MMP-12. Comparative Examples 3 and 4 maintained moderate inhibition (30-35%), but lower than that of Examples 1-3, indicating that glycine and soluble type 17 collagen also provided some additional synergistic effect, possibly involving osmotic protection and ECM stability. This experiment shows that the four-component synergy can achieve the optimal MMP-12 inhibition effect, among which kangaroo paw extract is an essential main active component, while amino acids and type 17 collagen play a synergistic and homeostatic support role.

[0082] like Figure 2 As shown, the Cyclin D1 expression levels in Examples 1, 2, and 3 were significantly better than those in Comparative Examples 1-4, indicating that the kangaroo paw flower-related formulations were more effective in upregulating Cyclin D1 expression. The differences among the three examples were minimal, all remaining at high levels, demonstrating that the formulations could stably promote Cyclin D1 expression at different concentrations or ratios. This suggests that kangaroo paw extract, arginine, glycine, and soluble type 17 collagen can exert a synergistic effect to promote Cyclin D1 expression.

[0083] Experimental Example 2

[0084] Effects of a composition containing kangaroo paw flower extract on the inflammatory factor TNF-α

[0085] 2.1 Test substance

[0086] The compositions of Examples 1-3 and the compositions of Comparative Examples 1-4 were used as test substances.

[0087] 2.2 Experimental Methods

[0088] Cell culture was performed as described above, with serum-free DMEM containing LPS (100 ng / mL) added and incubated at 37°C. The supernatant was aspirated, and the cells were washed once with ice-cold PBS. Total RNA was isolated according to the TRIzol standard procedure; purity was assessed by NanoDrop assay; if A260 / 280 < 1.8, purification could be repeated. A DNase I step could be added to remove the genomic DNA. 1 μg of RNA was used to reverse transcribe 20 μL of cDNA (a mixture of random primers and Oligo dT can accommodate both precursor and mature transcripts). The blank control group was not induced with LPS.

[0089] The primer sequences are as follows:

[0090] TNF-α forward primer: 5′-CCTCTCTCTAATCAGCCCTCTG-3′

[0091] TNF-α reverse primer: 5′-GAGGACCTGGGAGTAGATGAG-3′

[0092] β-Actin forward primer: 5′-AGAGCTACGAGCTGCCTGAC-3′

[0093] β-Actin reverse primer: 5′-AGCACTGTGTTGGCGTACAG-3′

[0094] Formula for calculating relative expression level:

[0095]

[0096] ΔCt q = Average Ct value of target gene in test group - Average Ct value of internal reference gene in test group

[0097] ΔCt cb = Average Ct value of target gene in control group - Average Ct value of internal reference gene in control group

[0098] 2.3 Experimental Results

[0099] Experimental results are as follows Figure 3 As shown.

[0100] Example 1 reduced TNF-α mRNA to approximately 36% (≈64% inhibition) in the model group, almost restoring it to baseline levels, showing the most significant inhibition. Examples 2 and 3 also significantly inhibited TNF-α mRNA expression. Comparative Example 1 reduced TNF-α by only about 10–15%, with no significant difference from the model group, indicating that kangaroo paw extract is the main anti-inflammatory driver. Comparative Example 2 showed an inhibition of approximately 25–30%, indicating that arginine can assist in reducing inflammation, but is not the core determinant. Comparative Examples 3 and 4 showed inhibition of approximately 35% and 40%, respectively, which are of moderate intensity, suggesting that both have a synergistic or homeostatic effect on the anti-inflammatory effect. Overall, the results indicate that the four components work synergistically to achieve the best TNF-α downregulation effect, with kangaroo paw extract being the essential main active ingredient, and amino acids and collagen peptides providing synergistic gains.

[0101] The above experimental results demonstrate that the composition of this invention, through the combination of kangaroo paw extract, arginine, glycine, and type 17 collagen, inhibits MMP-12 activity and reduces elastin fragment production; upregulates Cyclin D1 expression and activates the dermal papilla cell cycle; and reduces the level of the inflammatory factor TNF-α, restoring scalp homeostasis. In vitro model validation shows that this composition can achieve both matrix protection and enhanced cell vitality. The kangaroo paw extract, arginine, glycine, and type 17 collagen synergistically maintain hair follicle structure and stem cell activity, inhibit hair follicle miniaturization, prolong the growth phase, improve hair adhesion, improve the healthy microenvironment of scalp tissue, and significantly enhance the anti-hair loss effect, which is significantly superior to using any of the components alone.

[0102] Application Example 1

[0103] The scalp care composition containing kangaroo paw extract from Example 1 was applied to a shampoo.

[0104] The specific formula for the shampoo is as follows:

[0105] A shampoo containing kangaroo paw extract comprises, by weight percentage: 9% sodium C14-16 olefin sulfonate, 5% cocamidopropyl betaine, 3% sodium lauroyl sarcosinate, 2% cocamidopropyl MEA, 1% sodium cocoyl ethanesulfonate, 0.2% guar hydroxypropyl trimethylammonium chloride, 1% polydimethylsiloxane, 1% ethylene glycol distearate, 0.4% sodium benzoate, 0.5% phenoxyethanol, 0.25% trihydroxystearin, 0.1% sodium citrate, 0.2% citric acid, 0.1% disodium EDTA, 0.5% fragrance, 0.05% of the scalp care composition containing kangaroo paw extract of Example 1, with the balance being deionized water.

[0106] Application Example 2

[0107] The scalp care composition containing kangaroo paw extract from Example 1 was applied to a shampoo.

[0108] The specific formula for the shampoo is as follows:

[0109] A shampoo containing kangaroo paw extract comprises, by weight percentage: 9% sodium C14-16 olefin sulfonate, 5% cocamidopropyl betaine, 3% sodium lauroyl sarcosinate, 2% cocamidopropyl MEA, 1% sodium cocoyl ethanesulfonate, 0.2% guar hydroxypropyl trimethylammonium chloride, 1% polydimethylsiloxane, 1% ethylene glycol distearate, 0.4% sodium benzoate, 0.5% phenoxyethanol, 0.25% trihydroxystearin, 0.1% sodium citrate, 0.2% citric acid, 0.1% disodium EDTA, 0.5% fragrance, 0.3% of the scalp care composition containing kangaroo paw extract of Example 1, and the balance being deionized water.

[0110] Application Example 3

[0111] The scalp care composition containing kangaroo paw extract from Example 1 was applied to a shampoo.

[0112] The specific formula for the shampoo is as follows:

[0113] A shampoo containing kangaroo paw extract, by weight percentage, comprises the following ingredients: 9% sodium C14-16 olefin sulfonate, 5% cocamidopropyl betaine, 3% sodium lauroyl sarcosinate, 2% cocamidopropyl MEA, 1% sodium cocoyl ethanesulfonate, 0.2% guar hydroxypropyl trimethylammonium chloride, 1% polydimethylsiloxane, 1% ethylene glycol distearate, 0.4% sodium benzoate, 0.5% phenoxyethanol, 0.25% trihydroxystearin, 0.1% sodium citrate, 0.2% citric acid, 0.1% disodium EDTA, 0.5% fragrance, 1% of the scalp care composition containing kangaroo paw extract prepared in Example 1, and the balance being deionized water.

[0114] Application Example 4

[0115] The scalp care composition containing kangaroo paw extract from Example 1 was applied to a scalp serum.

[0116] The specific formula for the scalp serum is as follows:

[0117] A scalp serum containing kangaroo paw extract, by weight percentage, comprises the following ingredients: 5% butylene glycol, 3% propylene glycol, 0.05% xanthan gum, 0.6% p-hydroxyacetophenone, 0.8% 1,2-hexanediol, 0.02% disodium EDTA, 0.02% fragrance, 0.05% of the scalp care composition containing kangaroo paw extract of Example 1, and the balance being deionized water.

[0118] Application Example 5

[0119] The scalp care composition containing kangaroo paw extract from Example 1 was applied to a scalp serum.

[0120] The specific formula for the scalp serum is as follows:

[0121] A scalp serum containing kangaroo paw extract, by weight percentage, comprises the following ingredients: 5% butylene glycol, 3% propylene glycol, 0.05% xanthan gum, 0.6% p-hydroxyacetophenone, 0.8% 1,2-hexanediol, 0.02% disodium EDTA, 0.02% fragrance, 1% of the scalp care composition containing kangaroo paw extract of Example 1, and the balance being deionized water.

[0122] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention in any way. Therefore, any simple modifications, equivalent changes, and alterations made to the above embodiments based on the technical essence of the present invention without departing from the scope of the present invention shall still fall within the scope of the present invention.

Claims

1. A scalp care composition containing kangaroo paw extract, characterized in that, It includes the following components: kangaroo paw extract, arginine, glycine, and soluble type 17 collagen.

2. The scalp care composition according to claim 1, characterized in that, The scalp care composition comprises, by weight percentage, the following components: 2–10% kangaroo paw extract, 1–8% arginine, 1–5% glycine, and 0.05–0.5% soluble type 17 collagen.

3. The scalp care composition according to claim 1 or 2, characterized in that, The kangaroo paw extract was prepared by the following steps: dried petals of kangaroo paw flower were pulverized and refluxed with 70% ethanol at a mass-to-volume ratio of 1:10 at 70°C for 120 min; the supernatant was filtered and extracted a second time by refluxing with 70% ethanol for 60 min; the filtrates were combined and concentrated under reduced pressure at 55°C and -0.08 MPa to obtain a viscous extract, which was then spray-dried to obtain the kangaroo paw extract.

4. The scalp care composition according to claim 1 or 2, characterized in that, The scalp care composition also includes solvents and / or excipients.

5. The scalp care composition according to claim 4, characterized in that, The solvent is one or more of water, butanediol, and glycerol.

6. The scalp care composition according to claim 4, characterized in that, The excipients are one or more of p-hydroxyacetophenone, phenoxyethanol, sodium benzoate, and ethylhexylglycerin.

7. A method for preparing a scalp care composition as described in any one of claims 1 to 6, characterized in that, Includes the following steps: S1. Dissolve arginine and glycine in purified water at 65°C in sequence, and stir until clear; S2. Cool the solution to 45°C, add kangaroo paw extract, and stir until completely dissolved; S3. Maintain the temperature at 40°C, add soluble type 17 collagen, and stir until homogeneous to obtain the scalp care composition containing kangaroo paw extract.

8. A personal care product, characterized in that, It comprises a scalp care composition as described in any one of claims 1 to 6.

9. The washing and care product according to claim 8, characterized in that, The hair care products mentioned are any one of shampoo, hair serum, conditioner, and hair mask.

10. The use of the scalp care composition according to any one of claims 1 to 6 in any of the following: a) Inhibit the activity of matrix metalloproteinase MMP-12; b) Promotes Cyclin D1 expression; c) Inhibit the inflammatory response; d) Improve the healthy microenvironment of scalp tissue.

Images